Roche Elevates Thomas Schinecker to Chief Executive Officer in Leadership Transition

Roche Holding AG, the Swiss pharmaceutical giant, announced significant leadership changes that reshape its executive hierarchy. Most notably, Thomas Schinecker assumes the role of Chief Executive Officer starting March 15, 2023, marking a pivotal moment in the company’s leadership evolution. This appointment signals a continuation of Roche’s commitment to experienced internal talent as the foundation for future strategic direction.

Thomas Schinecker’s Rise Through Roche’s Leadership Ranks

Thomas Schinecker brings over two decades of experience within the organization, having joined Roche in 2003. His career trajectory demonstrates steady progression through various senior management positions, ultimately leading to his appointment as CEO of the Diagnostics Division in August 2019, where he also joined the Corporate Executive Committee. This extensive background in diagnostics—a critical growth sector for the pharmaceutical industry—positions him well to guide the entire organization. The promotion of Thomas Schinecker reflects the Board’s confidence in his strategic vision and operational expertise accumulated over nearly 20 years of service.

Severin Schwan Transitions to Chairman Role

The leadership restructuring extends beyond the CEO position. Severin Schwan, who has served as CEO since 2008 and led the company through significant market transformations, is set to assume the position of Chairman. The Board intends to formally propose this transition at the Annual General Meeting scheduled for March 14, 2023. Schwan’s extensive tenure—including his role as Corporate Executive Committee member since 2006 and Board member since 2013—ensures continuity and stable governance during the transition period. His move to Chairman enables a dedicated focus on strategic oversight while Thomas Schinecker assumes day-to-day operational responsibilities.

Board Changes and Departing Leadership

Christoph Franz, who served as Board Chairman since 2014 and had been a director since 2011, has decided not to seek re-election to the Board. His departure opens the pathway for Schwan’s promotion to the Chair position. This coordinated succession represents a carefully planned evolution of Roche’s governance structure, ensuring both strategic continuity and fresh executive perspectives under Thomas Schinecker’s leadership.